Rexahn Pharmaceuticals, Inc. Announces Advances In Phase I Cancer Clinical Trial

ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 14, 2006--Rexahn Pharmaceuticals (OTC BB:RXHN), a pharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer and disorders of the central nervous system, today announced the status of Phase I clinical trials of one of its leading oncology candidates, RX-0201. RX-0201 is a first-in-class signal inhibitor that directly blocks the production of Akt, a protein kinase, playing a key role in cancer progression.

Back to news